Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHaifaa AbdulhaqUniversity of California, San FranciscoGGGareth P. GregoryFiona Stanley HospitalJAJeremy S. AbramsonMassachusetts General Hospital

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved progression-free survival in relapsed DLBCL patients with Glofitamab plus GemOx, suggesting better outcomes.

Key Points

  • Glofitamab plus GemOx increased progression-free survival compared to R-GemOx in relapsed DLBCL.
  • The complete response rate was notably higher in patients receiving Glofitamab plus GemOx.
  • Randomized analysis across diverse patient subgroups confirmed the safety profile was consistent.
  • Adverse events primarily included gastrointestinal issues and cytokine release syndrome, especially in older patients.

Cite This Study

Abdulhaq et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d609https://doi.org/10.1182/blood-2025-3743
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations
  2. 2Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  5. 5Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis2025